Catalyst, in collaboration with the Emily Whitehead Foundation, publishes Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers

December 16, 2024

Understanding the patient experience with CAR-T long-term follow-up (LTFU) is essential for building a sustainable model. Catalyst Healthcare Consulting, in partnership with the Emily Whitehead Foundation, surveyed nearly 100 patients and caregivers to capture their perspectives.

The findings are outlined in the whitepaper Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers, which highlights the urgent need for patient-centered LTFU processes — an increasingly critical focus as more CAR T-cell therapies receive FDA approval and reach a growing number of patients

Recent News

Telework helps FDA compete for scientists. What if it’s no longer an option?

Read more

Cell & Gene Therapy is making swift progress, and Catalyst is keeping pace

Scientific innovation in Cell & Gene Therapy (C&GT) is advancing rapidly, sparking hope for patients with rare diseases, cancer, and other debilitating conditions

Read more

Recent blogs

Catalyst to Moderate DIA 2025 Panel on Enhancing Innovation in CGT Clinical Trials for Rare Disease

Join us for this dynamic conversation on Monday, June 16th, from 2:15–3:15 PM at DIA. We’d love to connect if you’ll be attending!

Read more

Catalyst to attend FDLI 2025 Annual Conference

If you are attending the FDLI conference, we would love to chat - reach out to us on LinkedIn!

Read more

The Catalyst Team shows support on Rare Disease Day

Being rare is often a blessing: a rare gem stands out from a pile of stones, a rare talent can garner prestige and success, and a rare personality can make for an influential leader or a cultural icon.

Read more